<?xml version="1.0" encoding="UTF-8"?>
<p>Our search yielded a total of 272 studies from the electronic databases. After sorting out repetitive hits, irrelevant and several single arm studies with various outcomes, e.g., dose escalation studies (
 <xref rid="B33" ref-type="bibr">Kodama et al., 2002</xref>; 
 <xref rid="B20" ref-type="bibr">Gao et al., 2003b</xref>; 
 <xref rid="B64" ref-type="bibr">Yoshimura et al., 2010</xref>; 
 <xref rid="B41" ref-type="bibr">Palomares et al., 2011</xref>; 
 <xref rid="B51" ref-type="bibr">Torkelson et al., 2012</xref>; 
 <xref rid="B38" ref-type="bibr">Ohno et al., 2013</xref>; 
 <xref rid="B49" ref-type="bibr">Suzuki et al., 2013</xref>; 
 <xref rid="B53" ref-type="bibr">Twardowski et al., 2015</xref>) as well as many publications on 
 <italic>in vitro</italic> and animal models, nine studies met our inclusion and exclusion criteria for a narrative review on medicinal mushrooms in human cancer therapy (eight RCTs, one CCT) (
 <xref rid="T1" ref-type="table">Table 1</xref>). A large variety of cancer entities, studied sample sizes, outcomes, treatment durations and observation times were seen (
 <xref rid="T1" ref-type="table">Table 1</xref>). The medicinal mushrooms investigated were 
 <italic>Agaricus sylvaticus</italic> (two trials) (
 <xref rid="B16" ref-type="bibr">Fortes et al., 2008</xref>; 
 <xref rid="B11" ref-type="bibr">Costa Fortes et al., 2010</xref>; 
 <xref rid="B10" ref-type="bibr">Costa Fortes and Carvalho Garbi Novaes, 2011</xref>; 
 <xref rid="B55" ref-type="bibr">Valadares et al., 2013</xref>), 
 <italic>Agaricus blazei murill</italic> (two trials) (
 <xref rid="B1" ref-type="bibr">Ahn et al., 2004</xref>; 
 <xref rid="B50" ref-type="bibr">Tangen et al., 2015</xref>), 
 <italic>Antrodia cinnamomea</italic> (one trial) (
 <xref rid="B52" ref-type="bibr">Tsai et al., 2016</xref>), 
 <italic>Coriolus versicolor</italic> (one trial) (
 <xref rid="B9" ref-type="bibr">Chay et al., 2017</xref>) and 
 <italic>Ganoderma lucidum</italic> (three trials) (
 <xref rid="B19" ref-type="bibr">Gao et al., 2003a</xref>; 
 <xref rid="B39" ref-type="bibr">Oka et al., 2010</xref>; 
 <xref rid="B67" ref-type="bibr">Zhao et al., 2012</xref>). All mushrooms were administered orally. Four articles were by Fortes et al. and they described different results of a study with 
 <italic>Agaricus sylvaticus</italic> which included 56 colorectal cancer patients (
 <xref rid="B16" ref-type="bibr">Fortes et al., 2008</xref>; 
 <xref rid="B15" ref-type="bibr">Fortes et al., 2009</xref>; 
 <xref rid="B11" ref-type="bibr">Costa Fortes et al., 2010</xref>; 
 <xref rid="B10" ref-type="bibr">Costa Fortes and Carvalho Garbi Novaes, 2011</xref>). These four articles were presented as one study. Most studies were named as placebo-controlled, double-blind RCTs. The methodological quality of most studies was generally unsatisfactory and most results were poorly reported in many aspects.
</p>
